Immunotherapy has emerged as a viable clinical strategy to harness endogenous anti-tumor
Introduction
CLL is one of the most common B-cell malignancies in adults, characterized by an accumulation of monoclonal CD5 + mature B-cells in lymphoid tissues and the peripheral blood. Clonal expansion and invasive migration typically causes the lymph nodes, spleen and the bone marrow to become infiltrated with tumor. Current standard therapy combines chemotherapy with an anti-CD20 mAb (chemoimmunotherapy, CIT). Although highly potent, CIT induces substantial toxicity and is not curative, with nearly all patients eventually relapsing. Recent advances using kinase inhibitors (e.g. ibrutinib and idelalisib) that target Bcell receptor (BCR) signaling, indicates an exciting shift towards a non-chemotherapy treatment era (reviewed by Jones and Byrd) 1 . Present indications suggest these drugs are not producing many complete responses and should be taken continuously to avoid relapse.
Unanswered questions include whether long-term persistent disease and prolonged therapy promote drug-resistant variants through clonal evolution and/or activation of compensatory oncogenic signaling in CLL. Ibrutinib resistance has already been detected in genetically high risk patients, 2 highlighting the necessity to identify combinatorial therapy using agents with distinct mechanism of action (MOA).
In addition to genome alterations, CLL exhibits another dimension of complexity:
leukemic cells are nurtured and protected from anti-cancer therapies by a variety of resident and recruited ostensibly normal cells that constitute the tumor microenvironment (TME) in lymphoid organs. Non-malignant components of the TME include: mesenchymal stromal/stem cells (MSCs), endothelial cells, tumor-associated macrophages (TAMs or 'nurse-like cells,'
NLCs), dendritic cells (DCs) and T-cells. A recent breakthrough in cancer therapeutics has
been the use of immunotherapies (immune checkpoint blockade) that target mechanisms of T-cell evasion by tumors. 3 In this review, we focus on the immunomodulatory drug (IMiD) lenalidomide that activates anti-tumor T-cell activity and is showing clinical activity in on-going CLL clinical trials. Lenalidomide (Revlimid®) is a derivative of thalidomide that is FDA approved for the treatment of multiple myeloma, myelodysplastic syndromes and mantle cell lymphoma. Remarkably, in contrast to the BCR inhibitor drugs, IMiDs exemplify successful bedside to bench research, in that their clinical effectiveness was known before recent MOA data emerged that help explain their pleotropic effects in the TME. For personal use only. on August 31, 2017. by guest www.bloodjournal.org From IMiDs increase the DC cross-priming, 16 expansion and activation of CD8 + T-cells while decreasing activated CD4 + T-cell-derived cytokines, 17 promote Th1 T-cell differentiation and polarize Th2 T-cells to a Th1 phenotype (IFN-γ, TNF-α). 1 This Th2 to Th1 switch is linked to increased expression of the transcription factor T-bet. 1 Lenalidomide repairs the tumor-induced T-cell immune synapse defect in CLL and lymphoma by increasing the assembly and activity of cytoskeletal signaling molecules including PKC-θ, WASp and Rho GTPase CDC42 to the synapse, allowing effective TCR/CD28 signal transduction and directional secretion of lytic granules. 7, 8 IMiD-mediated repair of NK-cell lytic synapse formation is also emerging. 1, 4 Lenalidomide also rescues T-cell motility in CLL by normalizing RAC1, RHOA and CDC42 activity levels. Importantly, knockdown of CRBN blocks lenalidomide repair of T-cell function. 18 Taken together, enhancement of T-cell-mediated responses by lenalidomide is linked to a re-targeted CRBN complex and altered transcription and activation of critical RHO GTPases. 8 Lenalidomide also alters RHO GTPase activation signaling that degrades malignant B-cell function (migration capability) and TME interactions (blocks pro-survival signaling interactions with NLCs). 19, 20 Up-regulation of co-stimulatory molecules such as CD80 and CLL cells position themselves in close contact with endothelial cells in the TME. 1 may interfere with the CXCR4-CXCL12 migratory axis in the CLL-TME (Figure 1iii ).
Clinical experience with lenalidomide
The initial dose of lenalidomide in CLL clinical trials was chosen based on experience in myeloma but this induced serious side-effects including rapid tumor cell death (tumor lysis syndrome, TLS) and acute inflammation (tumor flare reaction, TFR, that may be associated with immune-mediated clinical response). Therefore, a low initial dose with dose escalation has been applied in subsequent trials and has improved tolerability.
Published results discussed here are summarized and referenced in Experience with lenalidomide in the consolidation/maintenance setting has been limited. Results from a phase 2 trial of CIT followed by lenalidomide showed that 24% of patients improved their quality of response with consolidation and some converted to MRD negative status. 25 These results are encouraging for an active placebo-controlled phase 3 trial of lenalidomide maintenance in MRD positive patients post-CIT.
How to manage safety and toxicity?
The randomized ORIGIN trial that compared the safety and efficacy of front-line lenalidomide versus chlorambucil in elderly patients was halted by the FDA for safety concerns following an imbalance in the number of deaths in the lenalidomide treatment arm. This experience is in contrast to a trial reporting long-lasting efficacy with lenalidomide monotherapy 26 and TLS has been reported in 0-4.5% of patients from phase 2 studies. Slow dose escalation, close monitoring, and prophylaxis (e.g. allopurinol) can effectively prevent TLS.
Identifying biomarkers of response or resistance to improve patient care
The 
11
What is the future role of lenalidomide in the evolving treatment era?
Pre-clinical studies suggest that the PI3Kδ inhibitor idelalisib may antagonize the immunemodulating properties of lenalidomide including repair of the humoral defect. 29 
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